Comparative clinical and laboratory study of the original and generic platelet P2Y12 inhibitor ticagrelor in patients with stable coronary artery disease
Aim . To compare the laboratory (pharmacodynamic) efficacy, plasma concentrations, and safety of the original ticagrelor (OT, Brilinta) and generic ticagrelor (GT, Cardibrilin) at a dose of 60 mg twice daily in patients with stable coronary artery disease (CAD) at high ischemic risk. Material and methods . Thi...